BioAffinity Technologies (BIAF) announced the U.S. Patent and Trademark Office has issued a new patent covering a novel composition and method for selectively killing cancer by targeting the CD320 and LRP2 receptors on the cell membrane. The patent, “Compositions and Methods for Treating Cancer”, provides for use of the therapeutic approach with lung, breast, prostate, brain, and skin cancers. Research has begun toward developing a topical treatment for skin cancers.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIAF:
- bioAffinity Technologies Enters Sales Agreement with WallachBeth
- BioAffinity Technologies appoints Dr. Gordon Downie as Chief Medical Officer
- bioAffinity Technologies Sets 2025 Annual Meeting Date
- bioAffinity Technologies Reports Strong Q1 2025 Growth
- bioAffinity Technologies Completes $3.2M Public Offering